20.10
-0.50%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Syncom Formulations (India)
Its shares trade on NSE under the ticker SYNCOMF.NS. It has been listed since 24 January 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹4.89bn and net income of ₹764.4m. At that date it held total assets of ₹5.34bn and shareholders' equity of ₹4.15bn.
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh. The firm is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. The company is also engaged in the renting of properties. The company manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. The firm's domestic division product categories include Cratus Life Care, Cratus Evolve and Cratus Right Nutrition. Its products include Ciprofloxacin Tablets USP 250 mg, Ciprofloxacin Tablets USP 500 mg, Ciprofloxacin Tablets USP 750 mg, Cefazolin For Injection USP 1 gm, Cefotaxime For Injection USP 1 gm, Ceftriaxone for Injection USP 500 mg, Cefuroxime For Injection USP 750 mg and Gentamicin Injection BP 40 mg.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Jan 1994
- Employees
- 799
- Website
- syncomformulations.com ↗
Leadership
Pay as last reported
- Shri. Ankit BankdaWhole Time Chairman of the Board, since 2014
- Shri. Rahul BankdaChief Financial Officer
- Ms. Vaishali AgrawalCompliance Officer, Company Secretary
- Shri. Vijay BankdaManaging Director, Executive Director, since 1999₹6.4m
- Shri. Kedarmal BankdaWhole-Time Director, since 2007₹7.6m
- Smt. Ruchi JindalAdditional Woman Independent Director
- Mr. Ankit JainAdditional Non-Executive Independent Director
- Mr. Ritesh LunkadAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Syncom Formulations employs 799 full-time employees in Indore, Madhya Pradesh.
- The company manufactures and markets pharmaceutical formulations in various dosage forms including tablets and injections.
- Cratus Life Care, Cratus Evolve, and Cratus Right Nutrition are key domestic product categories.
Weaknesses
- Syncom Formulations has been listed since 24 January 1994, indicating a long-standing presence.
- The firm's product portfolio includes Ciprofloxacin and Cefazolin for injection USP products.
- Syncom Formulations engages in property renting alongside pharmaceutical manufacturing.
Opportunities
- Syncom Formulations operates in the Indian pharmaceutical sector with a focus on healthcare products.
- The company's domestic division targets health-conscious consumers through Cratus product lines.
- Syncom Formulations can expand its product range in the Indian market.
Threats
- Syncom Formulations faces competition in the Indian pharmaceutical market.
- The company's reliance on specific product lines like Ciprofloxacin may pose risks.
- Syncom Formulations must navigate regulatory changes in the Indian healthcare sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.